TVTX

Travere Therapeutics Inc. (TVTX) | Rumor.io

Travere Therapeutics

TVTX

Attention (50-day avg)0%

Attention rank (50-day avg)#935

Bullish sentiment (50-day avg)42%

Price to earnings ratio-212.3

Market capitalization5.8B

Earnings per share-0.73

Dividend yield (TTM)—

Revenue (annual)490.7M

Net income (annual)-25.5M

Social

What share of all stock conversation is about TVTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 5

Travere Therapeutics reported 2,012 patient start forms (PSFs) for Filspari in 2Q26, exceeding expectations.
Analysts have raised their price targets for the company, with Citi increasing its target to $85 from $70 and Stifel to $62 from $43.
The company's stock price surged 12% after Q2 results showed FILSPARI sales nearly doubled to $141M, fueled by strong FSGS launch and IgAN growth.

Generated by AI

Sentiment

Of the messages about TVTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +66.67	72.41% +24.63	83.6% -2.24
Bearish	—	0% -66.67	27.59% -24.63	16.4% +2.24

Bullish· Apr 15

$TVTX is breaking out at $42.13 with a 37.23% gain, driven by major institutional buying pressure and news on inducement grants.
The stock's technical indicators are strong, with a high volume of 14.94M confirming the breakout and a target technical price of $60.62.
The company's recent news on inducement grants and a special dividend declared are supporting the momentum, with buyers piling in on improved drug approval odds and sellers being squeezed out.

Bearish· Apr 13

The FDA issued a CRL (Complete Response Letter) for Travere Therapeutics' product, which is a significant setback for the company.
Insiders are loading up on buy orders before a potential news drop, indicating they may be aware of a positive development.
The company has a large short interest of 13.4 million shares, which could lead to a potential squeeze if the stock price rises.

Generated by AI

Topics

Of the messages about TVTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	56.76%	64.64%	51.71%
Technical Analysis	—	0%	26.52%	38.3%
Analysts	—	21.62%	4.42%	6.19%
Controversies	—	21.62%	4.42%	1.06%
Earnings	—	0%	0%	1.03%
Macro	—	0%	0%	1.71%

Analysts· Apr 14

Travere Therapeutics' ($TVTX) Travere Therapeutics price target maintained at $47 by HC Wainwright, reflecting continued confidence in the company’s outlook.
Canaccord raised the firm's price target on Travere Therapeutics to $56 from $47 and keeps a Buy rating on the shares, noting FDA approval for Filspari makes it the first and only approved therapy for FSGS.
BofA raised the firm's price target on Travere Therapeutics to $49 from $44 and keeps a Buy rating on the shares after the company announced FDA approval for Filspari's sNDA for FSGS.

Announcements· Apr 15

Travere Therapeutics ($TVTX) reports inducement grants under Nasdaq Listing Rule 5635(c)(4) on April 14, 2026, with shares surging to $42.13 (+37.23%).
FDA approval of Filspari for Travere Therapeutics ($TVTX) in focal segmental glomerulosclerosis (FSGS) marks the first FDA approval in FSGS based on a reduction in proteinuria, establishing a new revenue opportunity.
The FDA approval of Filspari for Travere Therapeutics ($TVTX) is seen as a label-expansion revenue event, adding ~$3B opportunity and expanding the company's presence in the renal growth leg.

Technical Analysis· Apr 14

$TVTX has broken out of a cup handle pattern, driven by FDA approval expanding the drug's market reach to broader rare kidney disease patients.
The stock has seen a significant surge of +34.30% to $41.23, with massive volume, indicating strong momentum and a potential continuation to $57.72.
The FDA approval has acted as a catalyst, fueling a high-conviction technical breakout, with the stock decisively breaching key resistance levels and targeting $61.72.

Generated by AI

Community

Of the messages about TVTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	82.76%	80.5%	49.54%
Newcomers	—	17.24%	19.5%	50.46%

Regulars· Aug 5

Citi raised the firm's price target on Travere Therapeutics to $85 from $70 and keeps a Buy rating on the shares.
Q2 results showed FILSPARI sales nearly doubled to $141M, fueled by strong FSGS launch and IgAN growth, with shares surging 12% on the news.
Analyst upgrades are expected, with multiple upgrades to the 70s and 80s, and one trader noting that 61 seems to be new resistance.

Newcomers· Apr 15

Newcomers are focused on the approval of Filspari in FSGS, which is a first-to-market treatment and has a large potential market of over 100,000 U.S. patients.
The surge in $TVTX is attributed to major institutional buying pressure, with the stock surging to $42.13, up 37.23% due to news on inducement grants.
The technical analysis indicates a strong breakout, with the stock violating the key resistance at $3506.64, and the volume elevated at 14.94M, confirming the momentum, with a technical target set at $6062.33.

Generated by AI

News

Travere at Stifel forum: FILSPARI growth offsets leadership shift

5d agoInvesting.com

Guggenheim raises Travere Therapeutics stock price target on patent

5d agoInvesting.com

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

Travere Therapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent

6d agoYahoo Finance

Travere receives patent allowance for FILSPARI use in FSGS

6d agoInvesting.com

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

SAN DIEGO, September 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain

7d agoYahoo Finance

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campbell has been appointed to succeed Dr. Dube, bringing experience from the rare disease biopharmaceutical sector. This CEO and President transition at Travere Therapeutics is an important development to set alongside the rest of the analysis. We have also...

7d agoYahoo Finance

Also Discussed

Investors talking about TVTX also mention

#	Name	Attention
1	UroGen Pharma Ltd.URGN	0%new
2	Grace Therapeutics, Inc.GRCE	0%new
3	Fortrea Holdings Inc.FTRE	0%0
4	Vestis CorporationVSTS	0%new
5	Dianthus Therapeutics Inc.DNTH	0%0
6	Mirum Pharmaceuticals, Inc.MIRM	0%0
7	Replimune Group, Inc.REPL	0%0
8	IDEAYA Biosciences Inc.IDYA	0%-0.01
9	Regenxbio Inc.RGNX	0%+0
10	Integra LifeSciences Holdings CorporationIART	0%0

Travere Therapeutics Inc.

Healthcare
Biotechnology

Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with rare kidney, liver, and metabolic diseases. Its current commercial portfolio includes FILSPARI, a treatment for certain kidney disorders, along with legacy rare-disease products such as Thiola, Thiola EC, Cholbam, and Chenodal. The company also supports specialized care through disease-focused programs and physician engagement aimed at addressing conditions with limited treatment options. Travere Therapeutics Inc. serves patients, healthcare providers, and rare-disease communities across its core therapeutic areas, combining approved medicines with ongoing development work in nephrology and metabolic disease. Headquartered in San Diego, California, Travere Therapeutics Inc. plays a notable role in the rare-disease biopharmaceutical market through its focused product set and concentrated clinical expertise.

Website

Location

3611 Valley Centre Drive

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about TVTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 5

Travere Therapeutics reported 2,012 patient start forms (PSFs) for Filspari in 2Q26, exceeding expectations.
Analysts have raised their price targets for the company, with Citi increasing its target to $85 from $70 and Stifel to $62 from $43.
The company's stock price surged 12% after Q2 results showed FILSPARI sales nearly doubled to $141M, fueled by strong FSGS launch and IgAN growth.

Generated by AI

Sentiment

Of the messages about TVTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +66.67	72.41% +24.63	83.6% -2.24
Bearish	—	0% -66.67	27.59% -24.63	16.4% +2.24

Bullish· Apr 15

$TVTX is breaking out at $42.13 with a 37.23% gain, driven by major institutional buying pressure and news on inducement grants.
The stock's technical indicators are strong, with a high volume of 14.94M confirming the breakout and a target technical price of $60.62.
The company's recent news on inducement grants and a special dividend declared are supporting the momentum, with buyers piling in on improved drug approval odds and sellers being squeezed out.

Bearish· Apr 13

The FDA issued a CRL (Complete Response Letter) for Travere Therapeutics' product, which is a significant setback for the company.
Insiders are loading up on buy orders before a potential news drop, indicating they may be aware of a positive development.
The company has a large short interest of 13.4 million shares, which could lead to a potential squeeze if the stock price rises.

Generated by AI

Topics

Of the messages about TVTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	56.76%	64.64%	51.71%
Technical Analysis	—	0%	26.52%	38.3%
Analysts	—	21.62%	4.42%	6.19%
Controversies	—	21.62%	4.42%	1.06%
Earnings	—	0%	0%	1.03%
Macro	—	0%	0%	1.71%

Analysts· Apr 14

Travere Therapeutics' ($TVTX) Travere Therapeutics price target maintained at $47 by HC Wainwright, reflecting continued confidence in the company’s outlook.
Canaccord raised the firm's price target on Travere Therapeutics to $56 from $47 and keeps a Buy rating on the shares, noting FDA approval for Filspari makes it the first and only approved therapy for FSGS.
BofA raised the firm's price target on Travere Therapeutics to $49 from $44 and keeps a Buy rating on the shares after the company announced FDA approval for Filspari's sNDA for FSGS.

Announcements· Apr 15

Travere Therapeutics ($TVTX) reports inducement grants under Nasdaq Listing Rule 5635(c)(4) on April 14, 2026, with shares surging to $42.13 (+37.23%).
FDA approval of Filspari for Travere Therapeutics ($TVTX) in focal segmental glomerulosclerosis (FSGS) marks the first FDA approval in FSGS based on a reduction in proteinuria, establishing a new revenue opportunity.
The FDA approval of Filspari for Travere Therapeutics ($TVTX) is seen as a label-expansion revenue event, adding ~$3B opportunity and expanding the company's presence in the renal growth leg.

Technical Analysis· Apr 14

$TVTX has broken out of a cup handle pattern, driven by FDA approval expanding the drug's market reach to broader rare kidney disease patients.
The stock has seen a significant surge of +34.30% to $41.23, with massive volume, indicating strong momentum and a potential continuation to $57.72.
The FDA approval has acted as a catalyst, fueling a high-conviction technical breakout, with the stock decisively breaching key resistance levels and targeting $61.72.

Generated by AI

Community

Of the messages about TVTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	82.76%	80.5%	49.54%
Newcomers	—	17.24%	19.5%	50.46%

Regulars· Aug 5

Citi raised the firm's price target on Travere Therapeutics to $85 from $70 and keeps a Buy rating on the shares.
Q2 results showed FILSPARI sales nearly doubled to $141M, fueled by strong FSGS launch and IgAN growth, with shares surging 12% on the news.
Analyst upgrades are expected, with multiple upgrades to the 70s and 80s, and one trader noting that 61 seems to be new resistance.

Newcomers· Apr 15

Newcomers are focused on the approval of Filspari in FSGS, which is a first-to-market treatment and has a large potential market of over 100,000 U.S. patients.
The surge in $TVTX is attributed to major institutional buying pressure, with the stock surging to $42.13, up 37.23% due to news on inducement grants.
The technical analysis indicates a strong breakout, with the stock violating the key resistance at $3506.64, and the volume elevated at 14.94M, confirming the momentum, with a technical target set at $6062.33.

Generated by AI

Travere Therapeutics

Social

Aug 5

Bullish· Apr 15

Bearish· Apr 13

Analysts· Apr 14

Announcements· Apr 15

Technical Analysis· Apr 14

Regulars· Aug 5

Newcomers· Apr 15

Travere at Stifel forum: FILSPARI growth offsets leadership shift

Guggenheim raises Travere Therapeutics stock price target on patent

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

Travere receives patent allowance for FILSPARI use in FSGS

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

Also Discussed

Travere Therapeutics Inc.

Company Information

Location

Travere at Stifel forum: FILSPARI growth offsets leadership shift

Guggenheim raises Travere Therapeutics stock price target on patent

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

Travere receives patent allowance for FILSPARI use in FSGS

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

Also Discussed

Social

Aug 5

Bullish· Apr 15

Bearish· Apr 13

Analysts· Apr 14

Announcements· Apr 15

Technical Analysis· Apr 14

Regulars· Aug 5

Newcomers· Apr 15